Home Remedies for Crohns Disease

No More Crohn's Disease

No More Crohn's Disease is a product of Cathy Rubert's personal research and many years of trial and error. This book reveals Cathys powerful 4-step plan against Chron's disease. You will learn about these 4 main natural steps that will immediately get rid of the pain in your lower abdomen. You will learn the single cheap ingredient that will bring your body's digestive system back in balance. This ingredient has the power to eliminate your pain in just days, no matter how bad your condition is. You too can start living a life free from Chrons disease with the help of her book.

No More Crohns Disease Summary


4.6 stars out of 11 votes

Contents: EBook
Author: Cathy Rubert
Price: $29.95

My No More Crohns Disease Review

Highly Recommended

This e-book comes with the great features it has and offers you a totally simple steps explaining everything in detail with a very understandable language for all those who are interested.

My opinion on this e-book is, if you do not have this e-book in your collection, your collection is incomplete. I have no regrets for purchasing this.

Download Now

Cured My Crohns

If you've ever gotten the fateful diagnosis you've got Crohns, you will know the massive upset that it can have on your way of life and how you feel about yourself and your relationship to other people. If you talk to your doctor about natural diets or some other method of curing your Crohns disease they will tell you that there is no way to fix it. However, there is often more to the story than modern medicine will tell you. New Age medicine is not a bunch of nonsense that hokey people subscribe to; New Age medicine fills in the gaps of knowledge that we have with modern medicine and helps us understand what is going on with our bodies. You will learn how to cure Crohns from someone who has cured it himself and has lived for over 10 years completely free of disease!

Cured My Crohns Summary

Contents: Ebook
Author: Alec Herring
Official Website: curedmycrohns.net
Price: $27.00

The Crohns And Ulcerative Colitis Bible

The Isaac protocol is backed with over 50.000 hours of nutritional expertise and most importantly centered on a groundbreaking research about underlying causes of the autoimmune reaction in Crohn\'s disease and ulcerative colitis (and I am not talking about eating wrong). It is also proven by over 250 case recovery studies officially submitted and approved as legit!

The Crohns And Ulcerative Colitis Bible Summary

Official Website: crohns-colitis-bible.com

Infliximab and adalimumab for Crohns disease May 2010

Infliximab or adalimumab is recommended for the treatment of severe active Crohn's disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications infliximab can also be used in a similar way in children over 6 years of age. In adults over 18 years of age, infliximab is recommended for the treatment of fistulating Crohn's disease that has not responded to conventional therapy (including antibacterials, drainage, and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications.

Fistulating Crohns disease Treatment may not be

Necessary for simple, asymptomatic perianal fistulas. Metronidazole (section 5.1.11) or ciprofloxacin (section 5.1.12) can improve symptoms of fistulating Crohn's disease but complete healing occurs rarely unlicensed indication . Metronidazole by mouth is used at a dose of 10-20 mg kg daily in divided doses (usual dose 400-500 mg 3 times daily) it is usually given for 1 month but no longer than 3 months because of concerns about peripheral neuropathy. Ciprofloxacin by mouth is given at a dose of 500 mg twice daily. Other antibacterials should be given if specifically indicated (e.g. sepsis associated with fistulas and perianal disease) and for managing bacterial overgrowth in the small bowel. Fistulas may also require surgical exploration and local drainage. Either azathioprine or mercaptopurine is used as a second-line treatment for fistulating Crohn's disease and continued for maintenance unlicensed indication . Infliximab is used for fistulating Crohn's disease refractory to...

Pathophysiological Changes

Inflammatory diseases of the GI tract like Morbus Crohn and ulcerative colitis greatly impair drug absorption. Depending on the condition, ulceration can be both in the upper or the lower intestine as well as in the colon. Changes in pH and ionic state may accompany the pathological condition, which further complicates dissolution of coating polymers and jeopardizes release or targeting, respectively, of the drug at the precise point of action. Few literature references exist describing the preceding with regard to the small intestine.

Inflammatory Bowel Disease in a Mouse Model

Crohn disease and ulcerative colitis are chronic inflammatory diseases of the gut that cause tremendous human suffering and loss of productivity. There is a clear need for better diagnostic tools that are less invasive or costly than endoscopy and histology. Torrence et al. published a study 7 of an inflammatory bowel disease model in mouse where they identified a serum-based IB pattern using data generated from a microsphere array. These data were generated using serum samples of mice infected with Helicobacter bilis, which causes an inflammation in the gut. These IB patterns were then compared with those of control animals. Samples were sent to Rules-Based Medicine (RBM), Inc., Austin, Texas for biomarker analysis using their RodentMAP (http www.rbmmaps.com). RBM has an automated testing laboratory that utilizes xMAP technology under regulatory compliance to both good laboratory practices (GLPs) and the Clinical Laboratory Improvement Act (CLIA). RBM performed a multianalyte profile...

Inflammatory bowel disease IBD

Ulcerative colitis and Crohn's disease are chronic diseases of unknown etiology that are characterized by recurrent inflammation and ulcerations of intestinal or colonic mucosa and inappropriate healing .96 The present basic therapy for IBD relies on classic anti-inflammatory and immunosuppressive drugs, such as glucocorticoids, mesalamine derivatives, azathioprine, and derivatives of the latter that vary in their ability to induce and maintain control of symptoms as well as in their tolerability and toxicities Great progress has been made over the last decade in the development of targeted specific therapies for IBD, e.g ., antibodies against TNF-a (infliximab) and

Chronic bowel disorders

Chronic inflammatory bowel diseases include ulcerative colitis and Crohn's disease. Effective management requires drug therapy, attention to nutrition, and in severe or chronic active disease, surgery. Aminosalicylates (balsalazide, mesalazine, olsalazine, and sulfasalazine), corticosteroids (hydrocortisone, beclometasone, budesonide, and prednisolone), and drugs that affect the immune response are used in the treatment of inflammatory bowel disease. Treatment of acute ulcerative colitis and Crohn's disease Acute mild to moderate disease affecting the rectum (proctitis) or the recto-sigmoid is treated initially with local application of an aminosalicylate (section 1.5.1) alternatively, a local corticosteroid can be used but it is less effective. A combination of a local amino-salicylate and a local corticosteroid can be used for proctitis that does not respond to a local aminosalicylate alone. Foam preparations and suppositories are especially useful when patients have difficulty...

Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) comprises several diseases, including ulcerative colitis and Crohn's disease. Ulcerative colitis is a disease of the colon, originating in the rectum and extending proximally to a variable extent. It frequently affects the entire colon but never causes significant involvement of the small intestine. Crohn's disease may affect any part of the gastrointestinal tract, although an ileocolitis is the most common localization. The aetiology of both diseases is unknown. Many humoral and immune phenomena are reputed to be involved, and it seems likely that immunological effector mechanisms are mainly responsible for causing chronic disease 14,24 . For instance, abnormal T cell responses to components of normal gut flora have been described 25 , and it has been suggested that deficiencies in suppressive regulatory T cells are involved in the pathogenesis of IBD 26 .

Intestinal inflammation

Chronic inflammatory diseases of the intestine, including Crohn's disease and chronic ulcerative colitis, are associated with a local over-production of pro-inflammatory cytokines while central immune cell activation causes the production of non-specific inflammatory mediators, which amplify the local immune response and promote tissue destruction (Fiorucci et al. 2004). In this context LXs exert their anti-inflammatory effects through several diverse mechanisms including the modulation of neutrophil transmigration across the intestinal epithelial monolayer, inhibition of leukocyte rolling and adherence, modulation of IL-8 release chemokine secretion, inhibition of TNF-a-induced neutrophil-enterocyte interaction, chemokine release and colonocyte apoptosis all of which are central to the physiological process of intestinal inflammation (Colgan et al. 1993 Goh et al. 2001 Gronert et al. 1998 Scalia et al. 1997) Several animal models of IBD have been developed (Elson et al. 1995)....

Therapeutic Antibodies

Another example of method claims is US patent 5,656,272 which describes the preparation of an anti-tumour necrosis factor-a chimeric antibody for treating Crohn's disease. This product has received US FDA approval. The patent claims are all directed to the method of treatment. A parallel patent application for the antibody itself may also exist.

Glucocorticoids With Very Little Or No Salt Retention

(Entocort), in oral capsules is used to treat Crohn disease. The affinity for the GC is approximately 200-fold greater than that of hydrocortisone and 15-fold greater than that of pred-nisolone. Budesonide is a mixture of epimers, with the 22R form having twice the affinity for the GR of the S epimer. This GC is metabolized by CYP3A4, and its levels can be increased in the presence of potent CYP3A4 inhibitors. Budesonide is also used in an inhaled formulation for the treatment of asthma (see next page).

Organic Cation Transporters Oct Octn Slc22A

Mutations in hOCTNs might increase susceptibility to Crohn's disease. Peltekova et al. (2004) first identified that a missense mutation in hOCTN1 gene and a transversion in the promoter region of hOCTN2, which form haplo-type related with an increase in the prevalence of Crohn's disease. The resulting amino acid change in hOCTN1 reduced its affinity and capacity for transporting carnitine. It, however, enhanced the affinity and uptake of other xenobiotics (Peltekova et al., 2004). The hOCTN2 promoter mutation occurred in the heat shock transcription factor binding element region and altered transcription factor binding affinity (Peltekova et al., 2004). Therefore, these variants alter transcription and transporter functions of the OCTNs and interact with variants in another gene associated with Crohn's disease, CARD15, to increase risk of Crohn's disease. The increased risk observed in this patient population was later confirmed by Torok et al. (2005).

Biological Influence of the Spacer in NOASA

Research in the field of hydrogen sulfide-releasing NSAIDs (HS-NSAIDs, Fig. 7) is in its infancy. To date, there have been no reports describing the effects of HS-NSAIDs in any in vitro studies of human cancer cell lines or in any in vivo animal models of cancer. There are some studies focusing on HS-diclofenac, HS-indomethacin, and HS-mesalamine for treatment and prevention of inflammatory bowl disease (IBD Crohn's disease and ulcerative colitis), also their anti-inflammatory properties, and GI-sparing effects have been described. IBD is a chronic disorder characterized by extensive ulceration and inflammation. The first-line therapy for mild-to-moderate IBD is up to 6g day of mesalamine (5-aminosalicylic acid), the mechanism of action of which is not well understood (Hanauer, 2006). The animal model used for evaluating various agents for treatment of IBD makes use of trinitrobenzene sulfonic acid (TNBS). This model is well characterized, and exhibits responsiveness to various...

Effects of Upstream and Downstream Processes

Several publications describe the association of coding polymorphisms in FCGR3A with responses to rituximab in oncology and autoimmunity trials (101105). Similar findings have been reported for FCGR2A, although it may be that these associations result from linkage within the genetic region encoding several FcRs (103). In vitro studies have shown that the FCGR3A variant 158V has higher affinity for IgG than the 158F variant, effectively broadening the concentration range in which Fc engagement activates ADCC in NK cells (106,107). Likewise, it has been observed that the anti-TNF mAb drugs may act as cell-targeting agents, since TNF-a is produced in a transmembrane form before release from the cell surface by cleavage (108). Recent studies of FCGR3A and infliximab therapy demonstrated that patients homozygous for the high-affinity 158V allele had a greater decrease in C-reactive protein, a PD marker in Crohn's disease, compared with 158F carriers. A follow-up study demonstrated that...

Pathological Processes in the Colon

The inflammatory bowel diseases of humans are regional enteritis, or Crohn's disease, and chronic ulcerative colitis 7 . These diseases are primarily treated with mesalazine, various corticosteroids and immunosuppressants. Crohn's disease is granulomatous and in most cases it is a simultaneous disease of the ileum and colon. The primarily inflamed region is the distal ileum, and all intestinal layers are thickened. The mucosal surface is reddened, nodular, and cobblestone-like, with multiple linear ulcerations.The mucosal layer is thickened by inflammatory infiltrate, the submucosa and serosa by fibrosis, and the serosa by hypertrophy. Chronic ulcerative colitis is a systemic disease that starts at the rectum or the sigmoid colon and progresses proximally to involve the entire left side of the colon.The colonic crypts are the first sites of cell damage and death, and the disease primarily involves the mucosal layer of the intestine.

Peptide and gene therapy related to bfGf and pdgf IN IBD

Recent clinical and animal studies suggest alteration and dysfunction of the intestinal microvasculature in IBD pathogenesis .99 101-105 One of these studies showed increased microvascular density in IBD mucosa, upregulation of VEGF, bFGF, TGFp, TNFa, and ET-1 . We also detected differential changes in the serum and tissue levels of bFGF and PDGF in patients with Crohn's disease and ulcerative colitis 106 More recently, we found a time-dependent increased expression of hypoxia-inducible transcription factor Egr-1 after iodoacetamide or TNBS administration into colonic mucosa in the rat models of IBD Based on our previous strategy about successful treatment of gastroduodenal ulcers by increasing levels of angiogenic growth factors bFGF and PDGF, which stimulate wound healing without increasing vascular permeability, we tested this approach for IBD therapy

Metabolism Of 6mercaptopurine And 6thioguanine

Thiopurines Mechanism Action

Recently, a novel mechanism was described. In a first approach, Tiede et al. (104) revealed that 6-thio-GTP bound to the GTPase Racl led to a mitochondrial pathway of apoptosis in CD3 and CD28 co-stimulated T-cells. These data are supported by the finding that patients with Crohn's disease responding to azathioprine had an increased rate of apoptotic cells in intestinal lamina propria cells in contrast to non-responders. In a clinical approach, a ratio of > 0.85 for 6-thio-GTP to 6-thio-GDP and 6-TGN levels of > 100 pmol per 8 x 108 RBC (ratio > 0.85 response in 81 ratio < 0.85 response in 36 ) turned out to be predictive of a response in Crohn's disease patients treated with azathioprine (105).

Disease States

There are a variety of other disease states whose influence on drug absorption has been reported, including cystic fibrosis, villous atrophy, celiac disease, diverticulosis, and Crohn's disease. The results of these studies are frequently divergent, and therefore general statements cannot be made. A thorough discussion of these findings is beyond the scope of this chapter.

NICE guidance

Adalimumab (section 1.5.3) is licensed for the treatment of severe active Crohn's disease in patients whose condition has not responded adequately to treatment with a corticosteroid and a conventional drug that affects the immune response, or who are intolerant of them. For inducing remission, adalimumab should be used in combination with a corticosteroid, but it may be given alone if a corticosteroid is inappropriate or is not tolerated. Adalimumab may also be used for Crohn's disease in patients who have relapsed while taking infliximab or who cannot tolerate infliximab because of hypersensitivity reactions. Maintenance of remission of acute ulcerative colitis and Crohn's disease Smoking cessation (section 4.10.2) reduces the risk of relapse in Crohn's disease and should be encouraged. Aminosalicylates are efficacious in the maintenance of remission of ulcer- ative colitis, but there is no evidence of efficacy in the maintenance of remission of Crohn's disease. Corticosteroids are...


Indications pruritus associated with partial biliary obstruction and primary biliary cirrhosis diarrhoea associated with Crohn's disease, ileal resection, vagotomy, diabetic vagal neuropathy, and radiation hypercholesterolaemia (section 2.12) Cautions section 2.12 Contra-indications section 2.12 Pregnancy section 2.12 Breast-feeding section 2.12 Side-effects section 2.12 Dose


The effects of glucocorticoids on the inflammatory response are numerous and well documented (see Chapter 59). Although glucocorticoids are universally recognized as effective in acute exacerbations, their use in either ulcerative colitis or Crohn's disease involves considerable challenges and pitfalls, and they are indicated only for moderate-to-severe IBD. Because the same issues impact steroid use in both ulcerative colitis and Crohn's disease, they are discussed together. Glucocorticoids sometimes are used for prolonged periods to control symptoms in steroid-dependent patients, but the failure to respond to glucocorticoids with prolonged remission (i.e., a disease relapse) should prompt consideration of alternative therapies, including immunosuppres-sives and infliximab (see below). Glucocorticoids are not effective in maintaining remission in either ulcerative colitis or Crohn's disease thus, their significant side effects have led to increased emphasis on limiting the duration...

Antitnf Therapy

Infliximab (remicade, cA2) is a chimeric immunoglobulin (25 mouse, 75 human) that binds to and neutralizes TNF-a, one of the principal cytokines mediating the TH1 immune response characteristic of Crohn's disease (see Figure 38-1). Infliximab (5 mg kg infused intravenously at intervals of several weeks to months) decreases the frequency of acute flares in approximately two-thirds of patients with moderate-to-severe Crohn's disease and also facilitates the closing of enterocutaneous fistulas associated with Crohn's disease. Its role in Crohn's disease is evolving, but emerging evidence supports its efficacy in maintaining remission and in preventing recurrence of fistulas. Infliximab therapy is associated with increased incidence of respiratory infections of particular concern is potential reactivation of tuberculosis or other granulomatous infections with subsequent dissemination. The FDA recommends that candidates for infliximab therapy should be tested for latent tuberculosis with...


An emerging concept is that a balance in the GI tract normally exists among the mucosal epithelium, the normal gut flora, and the immune response. Some data suggest that colonic bacteria may either initiate or perpetuate the inflammation of IBD, and specific bacterial antigens in the pathogenesis of Crohn's disease. Thus, certain bacterial strains may be either pro- (e.g., Bacteroides) or antiinflammatory (e.g., Lactobacillus), prompting attempts to manipulate the colonic flora in patients with IBD. Traditionally, antibiotics have been used to this end, most prominently in Crohn's disease. More recently, probiotics have been used to treat specific clinical situations in IBD. Antibiotics can be used as either (1) adjunctive treatment along with other medications for active IBD (2) treatment for a specific complication of Crohn's disease or (3) prophylaxis for recurrence in postoperative Crohn's disease. Metronidazole, ciprofloxacin, and clarithromycin are the antibiotics used most...


Sulfasalazine (Azufidine) is an azo prodrug that is reduced by the bacterium present in the lower intestine to its active metabolites, sulfapyridine and 5-aminosalicylic acid (5-ASA or mesalamine). It has been used for the treatment of RA or ankylosing spondylitis, and inflammatory bowel diseases (IBDs) such as ulcerative colitis and Crohn disease.


Displayed potential anti-cancer properties. Phillips and Petasis pioneered the research involving stabilisation of this key Cis_20 chain. Modification of the triene structure which is present in the native LX has been an active area of research. Incorporation of benzene or a heteroaromatic ring in place of this triene structure has had a number of enhanced properties, including stability towards enzymatic decomposition. Guiry and co-workers reported the first stereocontrolled synthesis of a benzene-containing analogue and found that it enhanced the phagocytosis of PMN by macrophages. Guiry and co-workers later published the synthesis of a novel analogue, where the triene had been replaced by a pyridine ring. They found that both epimers displayed potent anti-inflammatory characteristics. There have been fewer reports of structural modifications of the upper chain of the LX, mainly due to the importance of retaining the hydroxyl groups in order to maintain bio-activity. Guilford...


Electrolyte disturbance see also preparations below Contra-indications intestinal perforation or obstruction, paralytic ileus, severe inflammatory conditions of the intestinal tract (such as Crohn's disease, ulcer-ative colitis, and toxic megacolon), see also preparations below